Login to Your Account

Evotec Shares Fall with Terminated Roche Alliance

By Cormac Sheridan

Wednesday, May 25, 2011
Evotec AG is missing out on a potential $65 million payday following its decision to terminate a Phase II trial of EVT.101 in treatment-resistant depression.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription